to increase significantly complete response (CR) rate and event-free survival. 2 To maintain the homogeneity in the groups studied, patients with severe renal failure were usuMultiple myeloma with IgG kappa monoclonal gammopathy and oliguric renal failure requiring hemodialysis ally excluded from these therapeutic trials. Therefore, little is known about the tolerance of intensive therapeutic strawas diagnosed in a 49-year-old man. Conventional therapy with VAD (vincristin, adriamycin, dexamethasone) tegies in MM patients with severe renal failure. Here, we report a case of MM, with end-stage renal failure requiring failed to induce a complete response (CR) but this was subsequently obtained following two cycles of high-dose hemodialysis in whom intensive myeloblative therapy and PBSCT demonstrated a good therapeutic efficacy without intravenous melphalan (70 mg/m 2 ). A relapse occurred 8 months after CR which was treated by intensive myelincreasing the therapeutic toxicity. oablative therapy combining total body irradiation (6 Gy over 2 days) and high-dose intravenous melphalan (140 mg/m 2 ) followed by supportive PBSC transplanCase report tation. Hemodialysis was performed every other day during the myeloablative therapy and subsequent apla-A 49-year-old man was admitted in October 1992 because of asthenia, weight loss, back pain, nausea, vomiting and sia. Fluid subtraction allowed 1500 Cal/day intravenous alimentation and the only adverse event observed was oliguria. Biological explorations revealed anemia (Hb 97 g/l), severe renal failure (creatininemia = 1615 mol/l, a severe mucositis. A second CR was obtained which lasted 14 months. This observation indicates that mulurea = 31.2 mmol/l), increased calcemia (Ca ++ = 2.8 mol/l) and increased protidemia (86 g/l) in which tiple myeloma patients with end-stage renal failure can receive intensive myeloablative therapy without major immunofixation identified an IgG monoclonal gammopathy (IgG serum level = 29.15 g/l) with free light chains. toxicity. Keywords: multiple myeloma; melphalan; renal failure; More than 60% of the bone marrow cells were plasma cells in which cytogenetic analysis identified hypodiploidy (with hemodialysis; peripheral blood stem cell transplantation 41 chromosomes per cell) and structural abnormalities (dup 1q, t(1;11), t(15;21)). X-ray bone survey demonstrated a unique lytic lesion in D6. In this renal failure setting, the Renal failure is a common feature in multiple myeloma ␤2 microglobulin serum level was increased to 45.1 mg/l (MM). About 50% of patients showed a decrease in creatinwhile urine protein excretion was not analyzed due to the ine clearance at the time of diagnosis. Nine percent have anuria. The diagnosis of MM was retained and the disease severe renal failure which sometimes requires dialysis.
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More than 60% of the bone marrow cells were plasma cells in which cytogenetic analysis identified hypodiploidy (with hemodialysis; peripheral blood stem cell transplantation 41 chromosomes per cell) and structural abnormalities (dup 1q, t(1;11), t(15;21)). X-ray bone survey demonstrated a unique lytic lesion in D6. In this renal failure setting, the Renal failure is a common feature in multiple myeloma ␤2 microglobulin serum level was increased to 45.1 mg/l (MM). About 50% of patients showed a decrease in creatinwhile urine protein excretion was not analyzed due to the ine clearance at the time of diagnosis. Nine percent have anuria. The diagnosis of MM was retained and the disease severe renal failure which sometimes requires dialysis. 1 was classified as stage IIIB in the Durie and Salmon stagRenal failure is observed more frequently in MM patients ing system. demonstrating either hypercalcemia or high Bence-Jones Three consecutive daily plasma exchanges associated protein excretion or high tumour mass or IgD or light chain with high-dose methyl prednisolone (1 g/day for 3 days) type monoclonal component. Since 1983, intensive chemofailed to improve the renal function. Therefore, an arteriotherapy with high-dose intravenous melphalan in combivenous fistula was realized and the patient entered a hemonation with supportive autologous bone marrow transplandialysis program. Simultaneously, the patient received five tation or peripheral blood stem cell transplantation courses of VAD chemotherapy which combined continuous (PBSCT) has been widely used in the treatment of younger i.v. infusion of vincristine (0.4 mg/day) and adriamycin patients with MM. These therapies have been demonstrated (9 mg/m 2 /day) from day 1 to day 4 with i.v. bolus of dexamethasone (40 mg/day) from days 1 to 4, 9 to 12 and 17 to 20. This therapy failed to induce a complete response progressive increase of the serum monoclonal component diagnosis from refractory disease. The patient's evolution and treatments are summarized in Table 1 . was observed and two courses of high-dose intravenous melphalan (70 mg/m 2 on day 1) followed by subcutaneous G-CSF (30 g/day) from day 8 to granulocyte count recovery (periperal PMN Ͼ500/l) were administered. These Discussion two courses were clinically well tolerated and induced a 14-and 16-day neutropenia, respectively. A complete Renal failure is a common feature in MM patients at diagnosis. Conversely, when severe renal failure is not initially response, as defined by the disappearance of the monoclonal gammopathy in the patient's serum and the disappresent, the probability of the MM patients of developing ulterior renal impairment is very low. 1 Only 7% of MM pearance of plasmacytes in the bone marrow aspirate, was obtained. Interferon was administered subcutaneously three patients who initally require dialysis subsequently recover a renal function that is efficient enough to become indetimes a week for 4 months but then had to be interrupted due to severe thrombopenia. pendent of dialysis. 3 Renal failure is usually considered a bad prognosis factor. However, a survey of 561 patients A relapse was diagnosed 8 months after the last melphalan infusion. The therapeutic regimen consisted of two with MM 4 indicated that high tumor mass was the only independent parameter affecting survival of MM patients courses of VAD chemotherapy and one high-dose melphalan infusion followed by G-CSF administration. These whereas renal failure was not an independent prognostic factor. More than half of the patients with end-stage renal courses were performed at doses similar to those used for induction therapy. PBSC were collected by cytapheresis failure will benefit from more than 1 year survival. 5 Furthermore, these patients do not appear to die of ESRFafter the first course of VAD. Then, the patient was treated with total body irradiation (6 Gy over 2 days) combined related complications. For all these reasons, intensive chemotherapy, whose efficacy was clearly demonstrated in with bolus intravenous high-dose melphalan (140 mg/m 2 ). Autologous PBSC were infused 5 days after melphalan to MM patients without renal failure, may be beneficial for MM patients with high tumor burden and renal failure. prevent the destruction of transplanted stem cells by any residual cytotoxic drug in the patient's serum. The patient, Pharmacokinetic parameters of melphalan such as total body clearance, elimination half-life, steady-state volume isolated under laminar airflow, received G-CSF (300 g/day) from PBSC infusion to peripheral blood PMN of distribution, mean residence time and area under the plasma concentration time curve significantly correlate with count recovery (Ͼ500/l) and erythropoietin therapy was increased to 100 IU/kg, three times a week. Four hour creatinine clearance. 6,7 However, interindividual variations in the elimination of the drug are so large that a patient dialysis sessions were performed every other day (BL 747 Bellco unit, 40 l tank), with reduced anticoagulation with normal renal function may present slower kinetics than a patient with severe renal failure. In fact, high doses of (0.25 mg/kg enoxaparin) using a Gambrane membrane plate dialyzer. These regular dialyses permitted 1.5 l/day melphalan have been used in patients with end-stage renal failure without any major adverse event. 8, 9 The severe and intravenous alimentation (1500 Kcal/day). Aplasia lasted 10 days. The patient developed a WHO stage IV mucositis prolonged mucositis observed in the case reported may have resulted from an increased accumulation of melphalan for 5 days and a febrile episode of unknown origin that needed three courses of antibiotics. A second complete as a consequence of decreased renal clearance as well as of a lower circulating amino acid level which in turn modiresponse was obtained and the patient received 3 MUI alpha-interferon subcutaneously three times a week for 14 fied the intracellular uptake of the cytotoxic drug. 10 Better management of MM patients with end-stage renal failure months. An asymptomatic thrombopenia (40 000/l) was induced by this treatment but the patient, who received 80 could be obtained by: (1) performing preliminary test doses of the drug for individual dose adaptation; (2) infusing IU erythropoietin three times a week, did not require red cell transfusions at this time. A second relapse occurred 14 amino acids to prevent abnormal cellular uptake of the cytotoxic drug; (3) avoiding hemodialysis in the hours folmonths after PBSCT and the patient died 50 months after 
